References

References

1. Aedo S, Ivanova L, Tomova A, *et al.* Plasmid-related quinolone resistance determinants in epidemic *Vibrio parahaemolyticus*, uropathogenic *Escherichia coli*, and marine bacteria from an aquaculture area in Chile. *Microb Ecol* 2014; 68: 324-8.
2. Ahmed AM and Shimamoto T. Molecular characterization of multidrug-resistant *Shigella* spp. of food origin. *Int J Food Microbiol* 2015; 194: 78-82.
3. Aihara M, Sakai M, Iwasaki M, *et al.* [Isolation of enteropathogenic microorganism from patients with infection of the digestive tract during 1976 to 1988 in Tenri Hospital]. *Kansenshogaku zasshi* 1991; 65: 864-74.
4. Alekshun MN and Levy SB. Regulation of chromosomally mediated multiple antibiotic resistance: the *mar* regulon. *Antimicrob Agents Chemother* 1997; 41: 2067-75.
5. Amin AK and Wareham DW. Plasmid-mediated quinolone resistance genes in *Enterobacteriaceae* isolates associated with community and nosocomial urinary tract infection in East London, UK. *Int J Antimicrob Agents* 2009; 34: 490-1.
6. Andriole VT. The quinolones: past, present, and future. *Clin Infect Dis* 2005; 41 Suppl 2: S113-9.
7. Azmi IJ, Khajanchi BK, Akter F, *et al.* Fluoroquinolone resistance mechanisms of *Shigella flexneri* isolated in Bangladesh. *PLoS One* 2014; 9: e102533.
8. Ball P. Quinolone generations: natural history or natural selection? *J Antimicrob Chemother* 2000; 46 Suppl T1: 17-24.
9. Baranwal S, Dey K, Ramamurthy T, *et al.* Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of *Vibrio cholerae*. *Antimicrob Agents Chemother* 2002; 46: 2676-8.
10. Bauer AW, Kirby WM, Sherris JC *et al.* Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol* 1966; 45: 493-6.
11. Bauer A and Rorvik LM. A novel multiplex PCR for the identification of *Vibrio parahaemolyticus*, *Vibrio cholerae* and *Vibrio vulnificus*. *Lett Appl Microbiol* 2007; 45: 371-5.
12. Bax BD, Chan PF, Eggleston DS, *et al.* Type IIA topoisomerase inhibition by a new class of antibacterial agents. *Nature* 2010; 466: 935-40.
13. Bearden DT and Danziger LH. Mechanism of action of and resistance to quinolones. *Pharmacotherapy* 2001; 21: 224S-32S.
14. Begum A, Rahman MM, Ogawa W, *et al.* Gene cloning and characterization of four MATE family multidrug efflux pumps from *Vibrio cholerae* non-O1. *Microbiol Immunol* 2005; 49: 949-57.
15. Belotti PT, Thabet L, Laffargue A, *et al.* Description of an integron encompassing bla_{VIM-2}, *qnrVC1* and genes encoding bacterial group II intron proteins in *Pseudomonas aeruginosa*. *J Antimicrob Chemother* 2015; 70: 2237-40.
16. Bennish ML. Potentially lethal complications of Shigellosis. *Rev Infect Dis* 1991; 13 Suppl 4: S319-24.
17. Berger JM, Gamblin SJ, Harrison SC, *et al.* Structure and mechanism of DNA topoisomerase II. *Nature* 1996; 379: 225-32.

18. Birnboim HC and Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acids Res* 1979; 7: 1513–23.
19. Bhardwaj AK. "Multi-drug resisance in Vibrios: Never underestimate bacteria," in *Advances in Biotechnology,* I. K. International publishing house Pvt. Ltd. New Delhi. 2015; 91-105.
20. Bhardwaj AK and Mohanty P. Bacterial efflux pumps involved in multidrug resistance and their inhibitors: rejuvinating the antimicrobial chemotherapy. *Recent Pat Antiinfect Drug Discov* 2012; 7: 73–89.
21. Bhardwaj AK and Vinothkumar K. "EvolutionofMDRs,"in *Quorum Sensing vs Quorum Quenching: A Battle with No End in Sight,* Springer New Delhi 2015; 9-22.
22. Bhattacharjee S, Bal B, Pal R, *et al.* Is *Vibrio fluvialis* emerging as a pathogen with epidemic potential in coastal region of eastern India following cyclone Aila? *J Health Popul Nutr* 2010; 28: 311-7.
23. Bhattacharya D, Bhattacharjee H, Thamizhmani R, *et al.* Prevalence of the plasmid-mediated quinolone resistance determinants among clinical isolates of *Shigella* sp. in Andaman & Nicobar Islands, India. *Lett Appl Microbiol* 2011; 53: 247-51.
24. Bhattacharya D, Bhattacharya H, Thamizhmani R, *et al.* Shigellosis in Bay of Bengal Islands, India: clinical and seasonal patterns, surveillance of antibiotic susceptibility patterns, and molecular characterization of multidrug-resistant *Shigella* strains isolated during a 6-year period from 2006 to 2011. *Eur J Clin Microbiol Infect Dis* 2014; 33: 157-70.
25. Bolon MK. The newer fluoroquinolones. *Med Clin North Am* 2011; 95: 793-817.
26. Brown SA. Fluoroquinolones in animal health. *J Vet Pharmacol Ther* 1996; 19: 1-14.
27. Boulund F, Johnning A, Pereira MB, *et al.* A novel method to discover fluoroquinolone antibiotic resistance (*qnr*) genes in fragmented nucleotide sequences. *BMC Genomics* 2012; 13: 695.
28. Cattoir V, Poirel L, Mazel D, *et al. Vibrio splendidus* as the source of plasmid-mediated QnrS-like quinolone resistance determinants. *Antimicrob Agents Chemother* 2007; 51: 2650-1.
29. Cattoir V, Poirel L,Nordmann P. Plasmid-mediated quinolone resistance pump QepA2 in an *Escherichia coli* isolate from France. *Antimicrob Agents Chemother* 2008; 52: 3801-4.
30. Ceccarelli D, Hasan NA, Huq A, *et al.* Distribution and dynamics of epidemic and pandemic *Vibrio parahaemolyticus* virulence factors. *Front Cell Infect Microbiol* 2013; 3: 97.
31. Ceccarelli D, Spagnoletti M, Bacciu D *et al.* ICEVchInd5 is prevalent in epidemic *Vibrio cholerae* O1 El Tor strains isolated in India. *Int J Med Microbiol* 2011; 301: 318-24.
32. Chan M. Combat drug resistance: no action today means no cure tomorrow. Statement by WHO Director-General, Dr. Margaret Chan. World Health Day, 6th April 2011. (http://www.who.int/mediacentre/news/statements/2011/whd_20110407/en/)
33. Chakraborty R, Sinha S, Mukhopadhyay AK *et al.* Species-specific identification

of *Vibrio fluvialis* by PCR targeted to the conserved transcriptional activation and variable membrane tether regions of the *toxR* gene. *J Med Microbiol* 2006; 55: 805-8.

34. Chowdhury G, Pazhani GP, Dutta D, *et al. Vibrio fluvialis* in patients with diarrhea, Kolkata, India. *Emerg Infect Dis* 2012; 18: 1868-71.
35. Chowdhury G, Pazhani GP, Nair GB, *et al.* Transferable plasmid-mediated quinolone resistance in association with extended-spectrum beta-lactamases and fluoroquinolone-acetylating aminoglycoside-6'-N-acetyltransferase in clinical isolates of *Vibrio fluvialis*. *Int J Antimicrob Agents* 2011; 38: 169-73.
36. Clinical and Laboratory Standards Institute. Performance standards of antimicrobial disk susceptibility tests, *CLSI* 2010; Vol. 30 No.1.
37. Clinical and Laboratory Standards Institute. Performance standards of antimicrobial disk susceptibility tests, *CLSI* 2011; Vol. 31 No.1.
38. Cohen SP, McMurry LM, Hooper DC, *et al.* Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) *Escherichia coli* selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. *Antimicrob Agents Chemother* 1989; 33: 1318-25.
39. Cohen SP, Yan W and Levy SB. A multidrug resistance regulatory chromosomal locus is widespread among enteric bacteria. *J Infect Dis* 1993; 168: 484-8.
40. Collin F, Karkare S and Maxwell A. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. *Appl Microbiol Biotechnol* 2011; 92: 479-97.
41. Colquhoun DJ, Aarflot L and Melvold CF. *gyrA* and *parC* Mutations and associated quinolone resistance in *Vibrio anguillarum* serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway. *Antimicrob Agents Chemother* 2007; 51: 2597-9.
42. Colwell RR, Seidler RJ, Kaper J *et al.* Occurrence of *Vibrio cholerae* Serotype O1 in Maryland and Louisiana Estuaries. *Appl Environ Microbiol* 1981; 41: 555-8.
43. Dalhoff A. Global fluoroquinolone resistance epidemiology and implictions for clinical use. *Interdiscip Perspect Infect Dis* 2012; 2012: 976273.
44. Dalmasso A, Civera T and Bottero MT. Multiplex primer-extension assay for identification of six pathogenic vibrios. *Int J Food Microbiol* 2009; 129: 21-5.
45. Divya MP, Sivakumar KC, Sarada Devi KL *et al.* Novel multiple mutations in the topoisomerase gene of Haitian variant *Vibrio cholerae* O1. *Antimicrob Agents Chemother* 2014; 58: 4982-3.
46. Dougherty TJ, Beaulieu D and Barrett JF. New quinolones and the impact on resistance. *Drug Discov Today* 2001; 6: 529-36.
47. Drlica K, Hiasa H, Kerns R, *et al.* Quinolones: action and resistance updated. *Curr Top Med Chem* 2009; 9: 981-98.
48. Drlica K and Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. *Microbiol Mol Biol Rev* 1997; 61: 377-92.
49. Drlica K and Zhao X. Mutant selection window hypothesis updated. *Clin Infect Dis* 2007; 44: 681-8.

50. Dutta S, Jain P, Nandy S *et al.* Molecular characterization of serologically atypical provisional serovars of *Shigella* isolates from Kolkata, India. *J Med Microbiol* 2014; 63: 1696-703.
51. Dutta S, Kawamura Y, Ezaki T, *et al.* Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in Quinolone-resistant *Shigella dysenteriae* serotype 1 clinical isolates from Kolkata, India. *Antimicrob Agents Chemother* 2005; 49: 1660-1.
52. Dwyer DJ, Kohanski MA, Hayete B, *et al.* Gyrase inhibitors induce an oxidative damage cellular death pathway in *Escherichia coli*. *Mol Syst Biol* 2007; 3: 91.
53. Eliopoulos GM, Gardella A and Moellering RC, Jr. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. *Antimicrob Agents Chemother* 1984; 25: 331-5.
54. Faruque S, Albert M and Mekalanos J. Epidemiology, Genetics and Ecology of toxigenic *Vibrio cholerae*. *Microbiol Mol Biol R*ev 1998; 62: 1301-14.
55. Faruque SM and Nair GB. *Vibrio cholerae*: Genomics and Molecular Biology. Caister. Academic press 2008. ISBN: 9781904455332.
56. Ferreccio C, Prado V, Ojeda A, *et al.* Epidemiologic patterns of acute diarrhea and endemic *Shigella* infections in children in a poor periurban setting in Santiago, Chile. *Am J Epidemiol* 1991; 134: 614-27.
57. Fields PI, Popovic T, Wachsmuth K *et al.* Use of polymerase chain reaction for detection of toxigenic *Vibrio cholerae* O1 strains from the Latin American cholera epidemic. *J Clin Microbiol* 1992; 30: 2118-21.
58. Folster JP, Pecic G, Bowen A, *et al.* Decreased susceptibility to ciprofloxacin among *Shigella* isolates in the United States, 2006 to 2009. *Antimicrob Agents Chemother* 2011; 55: 1758-60.
59. Fonseca EL, Dos Santos Freitas F, Vieira VV, *et al.* New *qnr* gene cassettes associated with superintegron repeats in Vibrio cholerae O1. *Emerg Infect Dis* 2008; 14: 1129-31.
60. Fonseca EL and Vicente AC. Functional characterization of a Cassette-specific promoter in the class 1 integron-associated *qnrVC1* gene. *Antimicrob Agents Chemother* 2012; 56: 3392-4.
61. Fonseca EL and Vicente AC. Epidemiology of *qnrVC* alleles and emergence out of the *Vibrionaceae* family. *J Med Microbiol* 2013; 62: 1628-30.
62. Fu Y, Zhang W, Wang H, *et al.* Specific patterns of *gyrA* mutations determine the resistance difference to ciprofloxacin and levofloxacin in *Klebsiella pneumoniae* and *Escherichia coli*. *BMC Infect Dis* 2013; 13: 8.
63. Fujino T, Okuno Y, Nakada D, *et al.* On the bacteriological examination of shirasu-food poisoning. *Med J Osaka University* 1953; 4: 299–304.
64. Garrido MC, Herrero M, Kolter R, *et al.* The export of the DNA replication inhibitor Microcin B17 provides immunity for the host cell. *EMBO J* 1988; 7: 1853-62.
65. Ghosh A and Ramamurthy T. Antimicrobials & cholera: are we stranded? *Indian J Med Res* 2011; 133: 225-31.
66. Ghosh AS, Ahamed J, Chauhan KK, *et al.* Involvement of an efflux system in high-level fluoroquinolone resistance of *Shigella dysenteriae*. *Biochem Biophys Res Commun* 1998; 242: 54-6.

67. Ghosh S, Pazhani GP, Niyogi SK, *et al.* Genetic characterization of *Shigella* spp. isolated from diarrhoeal and asymptomatic children. *J Med Microbiol* 2014; 63: 903-10.
68. Good L, Awasthi SK, Dryselius R *et al.* Bactericidal antisense effects of peptide-PNA conjugates. *Nat Biotechnol* 2001; 19: 360-4.
69. Gu B, Cao Y, Pan S, *et al.* Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of *Shigella* between Europe-America and Asia-Africa from 1998 to 2009. *Int J Antimicrob Agents* 2012; 40: 9-17.
70. Hansen LH, Johannesen E, Burmolle M, *et al.* Plasmid-encoded multidrug efflux pump conferring resistance to olaquindox in *Escherichia coli*. *Antimicrob Agents Chemother* 2004; 48: 3332-7.
71. Hansen LH, Jensen LB, Sorensen HI, *et al.* Substrate specificity of the OqxAB multidrug resistance pump in *Escherichia coli* and selected enteric bacteria. *J Antimicrob Chemother* 2007; 60: 145-7.
72. Hansen LH, Sorensen SJ, Jorgensen HS, *et al.* The prevalence of the OqxAB multidrug efflux pump amongst olaquindox-resistant *Escherichia coli* in pigs. *Microb Drug Res* 2005; 11: 378-82.
73. Hata M, Suzuki M, Matsumoto M, *et al.* Cloning of a novel gene for quinolone resistance from a transferable plasmid in *Shigella flexneri* 2b. *Antimicrob Agents Chemother* 2005; 49: 801-3.
74. Heddle JG, Blance SJ, Zamble DB, *et al.* The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition. *J Mol Bio* 2001; 307: 1223-34.
75. Heddle J and Maxwell A. Quinolone-binding pocket of DNA gyrase: role of GyrB. *Antimicrob Agents Chemother* 2002; 46: 1805-15.
76. Hegde SS, Vetting MW, Mitchenall LA *et al.* Structural and biochemical analysis of the pentapeptide repeat protein *EfsQnr*, a potent DNA gyrase inhibitor. *Antimicrob Agents Chemother* 2011; 55: 110-17.
77. Hegde SS, Vetting MW, Roderick SL *et al.* A fluoroquinolone resistance protein from *Mycobacterium tuberculosis* that mimics DNA. *Science* 2005; 308: 1480-3.
78. Hernandez A, Sanchez MB and Martinez JL. Quinolone resistance: much more than predicted. *Front Microbiol* 2011; 2: 22.
79. Hoge CW, Watsky D, Peeler RN, *et al.* Epidemiology and spectrum of *Vibrio* infections in a Chesapeake Bay community. *J Infect Dis* 1989; 160: 985-93.
80. Hossain MT, Kim YR and Kong IS. PCR-restriction fragment length polymorphism analysis using *groEL* gene to differentiate pathogenic *Vibrio* species. *Diagn Microbiol Infect Dis* 2014; 78: 9-11.
81. Hu LF, Li JB, Ye Y, *et al.* Mutations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in clinical strains of fluoroquinolone-resistant *Shigella* in Anhui, China. *J Microbiol* 2007; 45: 168-70.
82. Huda MN, Chen J, Morita Y, *et al.* Gene cloning and characterization of VcrM, a Na+-coupled multidrug efflux pump, from *Vibrio cholerae* non-O1. *Microbiol Immunol* 2003; 47: 419-27.
83. Huq MI, Alam AK, Brenner DJ *et al.* Isolation of *Vibrio*-like group EF-6 from Patients with diarrhea. *J Clin Microbiol* 1980; 11:621-4.

84. Huq A, West PA, Small EB *et al.* Influence of water, temperature, salinity, and pH on survival and growth of toxigenic *Vibrio cholerae* serovar 01 associated with live copepods in laboratory microcosms. *Appl Environ Microbiol* 1984; 48: 420-4.
85. Ikeda H, Aoki K and Naito A. Illegitimate recombination mediated in vitro by DNA gyrase of *Escherichia coli*: structure of recombinant DNA molecules. *Proc Natl Acad Sci U S A* 1982; 79: 3724-8.
86. Ikeda H, Kawasaki I and Gellert M. Mechanism of illegitimate recombination: common sites for recombination and cleavage mediated by *E. coli* DNA gyrase. *Mol Gen Genet* 1984; 196: 546-9.
87. Ismail H, Smith AM, Sooka A, *et al.* Genetic characterization of multidrug-resistant, extended-spectrum- beta-lactamase-producing *Vibrio cholerae* O1 outbreak strains, Mpumalanga, South Africa, 2008. *J Clin Microbiol* 2011; 49: 2976-9.
88. Ismail H, Smith AM, Tau NP, *et al.* Cholera outbreak in South Africa, 2008-2009: laboratory analysis of *Vibrio cholerae* O1 strains. *J Infect Dis* 2013; 208 Suppl 1: S39-45.
89. Izumiya H, Matsumoto K, Yahiro S, *et al.* Multiplex PCR assay for identification of three major pathogenic *Vibrio* spp., *Vibrio cholera*, *Vibrio parahaemolyticus* and *Vibrio vulnificus*. *Mol Cell Probes* 2011; 25: 174-6.
90. Jacoby GA. Mechanisms of resistance to quinolones. *Clin Infect Dis* 2005; 41 Suppl 2: S120-6.
91. Jacoby G, Cattoir V, Hooper D, *et al. qnr* Gene nomenclature. *Antimicrob Agents Chemother* 2008; 52: 2297-9.
92. Jain S, Vashistt J and Changotra H. Rotaviruses: is their surveillance needed? *Vaccine* 2014; 32: 3367-78.
93. Jeon YL, Nam YS, Lim G, *et al.* Quinolone-resistant *Shigella flexneri* isolated in a patient who travelled to India. *Ann Lab Med* 2012; 32: 366-9.
94. Jeon B and Zhang Q. Sensitization of *Campylobacter jejuni* to fluoroquinolone and macrolide antibiotics by antisense inhibition of the CmeABC multidrug efflux transporter. *J Antimicrob Chemother* 2009; 63: 946-8.
95. Jeong JY, Kim ES, Choi SH *et al.* Effects of a plasmid-encoded *qnrA1* determinant in *Escherichia coli* strains carrying chromosomal mutations in the *acrAB* efflux pump genes. *Diagn Microbiol Infect Dis* 2008; 60: 105-107.
96. Jiang WP. [A study on diarrhoea disease caused by *Vibrionaceae* along coast the east of Zhejiang Province]. *Zhonghua yu fang yi xue za zhi* [Chinese journal of preventive medicine] 1991; 25: 335-7.
97. Jiang Y, Yao L, Li F, *et al.* Characterization of antimicrobial resistance of *Vibrio parahaemolyticus* from cultured sea cucumbers (Apostichopus japonicas). *Lett Appl Microbiol* 2014; 59: 147-54.
98. Kakinuma Y, Maeda Y, Mason C, *et al.* Molecular characterisation of the quinolone resistance-determining regions (QRDR) including *gyrA*, *gyrB*, *parC* and *parE* genes in *Streptococcus pneumoniae*. *Br J Biomed Sci* 2012; 69: 123-5.
99. Kampranis SC and Maxwell A. The DNA gyrase-quinolone complex. ATP hydrolysis and the mechanism of DNA cleavage. *J Biol Chem* 1998; 273: 22615-26.

100. Kanungo S, Sah BK, Lopez AL *et al.* Cholera in India: an analysis of reports, 1997-2006. *Bull World Health Organ* 2010; 88: 185-91.
101. Kanungo S, Sur D, Ali M, *et al.* Clinical, epidemiological, and spatial characteristics of *Vibrio parahaemolyticus* diarrhea and cholera in the urban slums of Kolkata, India. *BMC Public Health* 2012; 12: 830.
102. Khuntia HK, Pal BB and Chhotray GP. Quadruplex PCR for simultaneous detection of serotype, biotype, toxigenic potential, and central regulating factor of *Vibrio cholerae*. *J Clin Microbiol* 2008; 46: 2399-2401.
103. Kim MN and Bang HJ. Detection of marine pathogenic bacterial *Vibrio* species by multiplex polymerase chain reaction (PCR). *J Environ Biol* 2008; 29: 543-6.
104. Kim E and Hooper DC. Clinical importance and epidemiology of quinolone resistance. *Infect Chemother* 2014; 46: 226-38.
105. Kim HB, Wang M, Ahmed S, *et al.* Transferable quinolone resistance in *Vibrio cholerae*. *Antimicrob Agents Chemother* 2010; 54: 799-803.
106. Kim ES, Jeong JY, Choi SH, *et al.* Plasmid-mediated fluoroquinolone efflux pump gene, *qepA*, in *Escherichia coli* clinical isolates in Korea. *Diagn Microbiol Infect Dis* 2009; 65: 335-8.
107. Kim J, Jeon S, Kim H, *et al.* Multiplex Real-Time Polymerase Chain Reaction-Based Method for the Rapid Detection of *gyrA* and *parC* Mutations in Quinolone-Resistant *Escherichia coli* and *Shigella* spp. *Osong Public Health Res Perspect* 2012; 3: 113-7.
108. Kim JY, Kim SH, Jeon SM, *et al.* Resistance to fluoroquinolones by the combination of target site mutations and enhanced expression of genes for efflux pumps in *Shigella flexneri* and *Shigella sonnei* strains isolated in Korea. *Clin Microbiol Infect* 2008; 14: 760-5.
109. Kim HJ, Ryu JO, Lee SY *et al.* Multiplex PCR for detection of the *Vibrio* genus and five pathogenic *Vibrio* species with primer sets designed using comparative genomics. *BMC Microbiol* 2015; 15: 239.
110. Kitaoka M, Miyata ST, Unterweger D, *et al.* Antibiotic resistance mechanisms of *Vibrio cholerae*. *J Med Microbiol* 2011; 60: 397-407.
111. Kitiyodom S, Khemtong S, Wongtavatchai J, *et al.* Characterization of antibiotic resistance in *Vibrio* spp. isolated from farmed marine shrimps (Penaeus monodon). *FEMS Microbiol Ecol* 2010; 72: 219-27.
112. Klontz KC and Desenclos JC. Clinical and epidemiological features of sporadic infections with *Vibrio fluvialis* in Florida, USA. *J Diarrhoeal Dis Res* 1990; 8: 24-6.
113. Kohanski MA, Dwyer DJ and Collins JJ. How antibiotics kill bacteria: from targets to networks. *Nat Rev Microbiol* 2010; 8: 423-35.
114. Kohanski MA, Dwyer DJ, Hayete B, *et al.* A common mechanism of cellular death induced by bactericidal antibiotics. *Cell* 2007; 130: 797-810.
115. Kosek M, Bern C and Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. *Bull World Health Organ* 2003; 81: 197-204.
116. Kotloff KL, Winickoff JP, Ivanoff B, *et al.* Global burden of *Shigella* infections: implications for vaccine development and implementation of control strategies. *Bull World Health Organ* 1999; 77: 651-66.

117. Kumar P, Mishra DK, Deshmukh DG *et al.* Haitian variant *ctxB* producing *Vibrio cholerae* O1 with reduced susceptibility to ciprofloxacin is persistent in Yavatmal, Maharashtra, India, after causing a cholera outbreak. *Clin Microbiol Infect* 2014; 20: O292-3.
118. Kumar P and Thomas S. Presence of *qnrVC3* gene cassette in SXT and class 1 integrons of *Vibrio cholerae*. *Int J Antimicrob Agents* 2011; 37: 280-1.
119. Kutar BM, Rajpara N, Upadhyay H, *et al.* Clinical isolates of *Vibrio cholerae* O1 El Tor Ogawa of 2009 from Kolkata, India: preponderance of SXT element and presence of Haitian *ctxB* variant. *PLoS One* 2013; 8: e56477.
120. Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. *Nature* 1970; 227: 680-5.
121. Laponogov I, Sohi MK, Veselkov DA, *et al.* Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. *Nat Struct Mol Biol* 2009; 16: 667-9.
122. Laponogov I, Pan XS, Veselkov DA, *et al.* Structural basis of gate-DNA breakage and resealing by type II topoisomerases. *PLoS One* 2010; 5: e11338.
123. Lee JV, Shread P, Furniss AL, *et al.* Taxonomy and description of *Vibrio fluvialis* sp. nov. (synonym group F vibrios, group EF6). *J Appl Bacteriol* 1981; 50: 73-94.
124. Lesmana M, Subekti DS, Tjaniadi P, *et al.* Spectrum of vibrio species associated with acute diarrhea in North Jakarta, Indonesia. *Diagn Microbiol Infect Dis* 2002; 43: 91-7.
125. Levine WC and Griffin PM. Vibrio infections on the Gulf Coast: results of first year of regional surveillance. Gulf Coast Vibrio Working Group. *J Infect Dis* 1993; 167: 479-83.
126. Li X, Zhao X and Drlica K. Selection of *Streptococcus pneumoniae* mutants having reduced susceptibility to moxifloxacin and levofloxacin. *Antimicrob Agents Chemother* 2002; 46: 522-4.
127. Libinzon AE, Levanova GF and Gal'tseva GV. [The isolation of *Vibrio fluvialis* on the territory of the USSR]. *Zh Mikrobiol Epidemiol Immunobiol* 1991; 20-3.
128. Liu M and Chen S. Draft genome sequence of *Vibrio parahaemolyticus* V110, isolated from shrimp in Hong Kong. *Genome Announc* 2013; 1:e300-e313.
129. Liu M, Wong MH and Chen S. Molecular characterisation of a multidrug resistance conjugative plasmid from *Vibrio parahaemolyticus*. *Int J Antimicrob Agents* 2013; 42: 575-9.
130. Liu Y, Hu L, Pan Y, *et al.* Prevalence of plasmid-mediated quinolone resistance determinants in association with beta-lactamases, 16S rRNA methylase genes and integrons amongst clinical isolates of *Shigella flexneri*. *J Med Microbiol* 2012; 61: 1174-6.
131. Lomovskaya O, Lee A, Hoshino K *et al.* Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1999; 43: 1340-6.
132. Ma J, Zeng Z, Chen Z, *et al.* High prevalence of plasmid-mediated quinolone resistance determinants *qnr*, *aac(6')-Ib-cr*, and *qepA* among ceftiofur-resistant *Enterobacteriaceae* isolates from companion and food-producing animals. *Antimicrob Agents Chemother* 2009; 53: 519-24.

133. Magalhaes V, Lima RA, Magalhaes E, *et al.* [Human gastroenteritis associated with *Vibrio fluvialis* in Recife]. *Arq Gastroenterol* 1990; 27: 141-3.
134. Malik M, Zhao X and Drlica K. Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. *Mol Microbiol* 2006; 61: 810-25.
135. Mandal S, Mandal MD and Pal NK. Cholera: a great global concern. *Asian Pac J Trop Med* 2011; 4: 573-80.
136. Marcusson LL, Olofsson SK, Komp Lindgren P *et al.* Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of *Escherichia coli*. *J Antimicrob Chemother* 2005; 55: 938-43.
137. Marin MA, Thompson CC, Freitas FS, *et al.* Cholera outbreaks in Nigeria are associated with multidrug resistant atypical El Tor and non-O1/non-O139 *Vibrio cholerae*. *PLoS Negl Trop Dis* 2013; 7: e2049.
138. Martinez-Martinez L, Pascual A, Garcia I *et al.* Interaction of plasmid and host quinolone resistance. *J Antimicrob Chemother* 2003; 51: 1037-9.
139. Martinez-Martinez L, Pascual A and Jacoby GA. Quinolone resistance from a transferable plasmid. *Lancet* 1998; 351: 797-9.
140. Mensa L, Marco F, Vila J, *et al.* Quinolone resistance among *Shigella* spp. isolated from travellers returning from India. *Clin Microbiol Infect* 2008; 14: 279-81.
141. Mohanty P, Patel A and Kushwaha Bhardwaj A. Role of H- and D- MATE-type transporters from multidrug resistant clinical isolates of *Vibrio fluvialis* in conferring fluoroquinolone resistance. *PLoS One* 2012; 7: e35752.
142. Morais Cabral JH, Jackson AP, Smith CV, *et al.* Crystal structure of the breakage-reunion domain of DNA gyrase. *Nature* 1997; 388: 903-6.
143. Morita Y, Kataoka A, Shiota S, *et al.* NorM of *Vibrio parahaemolyticus* is an Na(+)-driven multidrug efflux pump. *J Bacteriol* 2000; 182: 6694-7.
144. Morita Y, Kodama K, Shiota S, *et al.* NorM, a putative multidrug efflux protein, of *Vibrio parahaemolyticus* and its homolog in *Escherichia coli*. *Antimicrob Agents Chemother* 1998; 42: 1778-82.
145. Murray MG and Thompson WF. Rapid isolation of high molecular weight plant DNA. *Nucleic Acids Res* 1980; 8: 4321-5.
146. Nair GB, Ramamurthy T, Bhattacharya SK, *et al.* Global dissemination of *Vibrio parahaemolyticus* serotype O3:K6 and its serovariants. *Clin Microbiol Rev* 2007; 20: 39-48.
147. Nandy S, Mitra U, Rajendran K *et al.* Subtype prevalence, plasmid profiles and growing fluoroquinolone resistance in *Shigella* from Kolkata, India (2001-2007): a hospital-based study. *Trop Med Int Health* 2010; 15: 1499-507.
148. Niyogi SK. Shigellosis. *J Microbiol* 2005; 43: 133-43.
149. O'Donnell JA and Gelone SP. The newer fluoroquinolones. *Infect Dis Clin North Am* 2004; 18: 691-716.
150. Olsvik O, Wahlberg J, Petterson B *et al.* Use of automated sequencing of polymerase chain reaction-generated amplicons to identify three types of cholera toxin subunit B in *Vibrio cholerae* O1 strains. *J Clin Microbiol* 1993; 31:22-25.
151. Okada K, Na-Ubol M, Natakuathung W, *et al.* Comparative genomic characterization of a Thailand-Myanmar isolate, MS6, of *Vibrio cholerae* O1 El

Tor, which is phylogenetically related to a "US Gulf Coast" clone. *PLoS One* 2014; 9: e98120.

152. Okuda J, Hayashi N, Wakahara Y, *et al.* Reduced expression of the vca0421 gene of *Vibrio cholerae* O1 results in innate resistance to ciprofloxacin. *Antimicrob Agents Chemother* 2010; 54: 4917-9.
153. Okuda J, Ishibashi M, Hayakawa E, *et al.* Emergence of a unique O3:K6 clone of *Vibrio parahaemolyticus* in Calcutta, India, and isolation of strains from the same clonal group from Southeast Asian travelers arriving in Japan. *J Clin Microbiol* 1997; 35: 3150-5.
154. Okumura R, Liao CH, Gavin M, *et al.* Quinolone induction of *qnrVS1* in *Vibrio splendidus* and plasmid-carried *qnrS1* in *Escherichia coli*, a mechanism independent of the SOS system. *Antimicrob Agents Chemother* 2011; 55: 5942-5.
155. Otsuka M, Yasuda M, Morita Y, *et al.* Identification of essential amino acid residues of the NorM Na+/multidrug antiporter in *Vibrio parahaemolyticus*. *J Bacteriol* 2005; 187: 1552-8.
156. Pazhani GP, Bhowmik SK, Ghosh S, *et al.* Trends in the epidemiology of pandemic and non-pandemic strains of *Vibrio parahaemolyticus* isolated from diarrheal patients in Kolkata, India. *PLoS Negl Trop Dis* 2014; 8: e2815.
157. Pazhani GP, Niyogi SK, Singh AK, *et al.* Molecular characterization of multidrug-resistant *Shigella* species isolated from epidemic and endemic cases of shigellosis in India. *J Med Microbiol* 2008; 57: 856-63.
158. Perichon B, Courvalin P and Galimand M. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in *Escherichia coli*. *Antimicrob Agents Chemother* 2007; 51: 2464-9.
159. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. *Clin Microbiol Rev* 2006; 19: 382-402.
160. Po KH, Wong MH and Chen S. Identification and characterisation of a novel plasmid-mediated quinolone resistance gene, *qnrVC7*, in *Vibrio cholerae* of seafood origin. *Int J Antimicrob Agents* 2015; 45: 667-8.
161. Pons MJ, Gomes C and Ruiz J. QnrVC, a new transferable Qnr-like family. *Enferm Infecc Microbiol Clin* 2013; 31: 191-192.
162. Poirel L, Liard A, Rodriguez-Martinez JM, *et al.* *Vibrionaceae* as a possible source of Qnr-like quinolone resistance determinants. *J Antimicrob Chemother* 2005a; 56: 1118-21.
163. Poirel L, Rodriguez-Martinez JM, Mammeri H, *et al.* Origin of plasmid-mediated quinolone resistance determinant QnrA. *Antimicrob Agents Chemother* 2005b; 49: 3523-5.
164. Pu XY, Pan JC, Gu YM *et al.* Complete sequences and characterization of two novel plasmids carrying *aac(6')-Ib-cr* and *qnrS* gene in *Shigella flexneri*. *Microb Drug Resist* 2015. [Ahead of print]
165. Pu XY, Pan JC, Wang HQ, *et al.* Characterization of fluoroquinolone-resistant *Shigella flexneri* in Hangzhou area of China. *J Antimicrob Chemother* 2009; 63: 917-20.
166. Pu XY, Pan JC, Zhang W *et al.* Quinolone resistance-determining region mutations and the plasmid-mediated quinolone resistance gene *qnrS* played

important roles in decreased susceptibility to fluoroquinolones among *Shigella* isolates in southeast China between 1998 and 2013. *Int J Antimicrob Agents* 2015; 45: 438-9.

167. Pu XY, Zhang Q, Pan JC, *et al.* Spontaneous mutation frequency and molecular mechanisms of *Shigella flexneri* fluoroquinolone resistance under antibiotic selective stress. *World J Microbiol Biotechnol* 2013; 29: 365-71.
168. Quilici ML, Massenet D, Gake B, *et al. Vibrio cholerae* O1 variant with reduced susceptibility to ciprofloxacin, Western Africa. *Emerg Infect Dis* 2010; 16: 1804-5.
169. Rajpara N, Patel A, Tiwari N, *et al.* Mechanism of drug resistance in a clinical isolate of *Vibrio fluvialis*: involvement of multiple plasmids and integrons. *Int J Antimicrob Agents* 2009; 34: 220-5.
170. Ramamurthy T, Chowdhury G, Pazhani GP, *et al. Vibrio fluvialis*: an emerging human pathogen. *Front Microbiol* 2014; 5: 91.
171. Ramani S and Kang G. Viruses causing childhood diarrhoea in the developing world. *Curr Opin Infect Dis* 2009; 22: 477-82.
172. Robicsek A, Strahilevitz J, Jacoby GA, *et al.* Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. *Nat Med* 2006; 12: 83-8.
173. Rodkhum C, Maki T, Hirono I, *et al.* gyrA and parC associated with quinolone resistance in *Vibrio anguillarum*. *J Fish Dis* 2008; 31: 395-9.
174. Rodriguez-Martinez JM, Cano ME, Velasco C, *et al.* Plasmid-mediated quinolone resistance: an update. *J Infect Chemother* 2011; 17: 149-82.
175. Roig FJ, Llorens A, Fouz B, *et al.* Spontaneous quinolone resistance in the zoonotic serovar of *Vibrio vulnificus*. *Appl Environ Microbiol* 2009; 75: 2577-80.
176. Roy A, Kucukural A and Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. *Nat Protoc* 2010; 5: 725-38.
177. Roy A, Yang J and Zhang Y. COFACTOR: an accurate comparative algorithm for structure-based protein function annotation. *Nucleic Acids Res* 2012; 40: W471-477.
178. Ruekit S, Wangchuk S, Dorji T, *et al.* Molecular characterization and PCR-based replicon typing of multidrug resistant *Shigella sonnei* isolates from an outbreak in Thimphu, Bhutan. *BMC Res Notes* 2014; 7: 95.
179. Rushdy AA, Mabrouk MI, Abu-Sef FA, *et al.* Contribution of different mechanisms to the resistance to fluoroquinolones in clinical isolates of *Salmonella enterica*. *Braz J Infect Dis* 2013; 17: 431-7.
180. Sack DA, Lyke C, McLaughlin C, *et al.*, Antimicrobial resistance in shigellosis, cholera and campylobacteriosis. *World Health Organization* 2001; pp. 1-20.
181. Saga T, Kaku M, Onodera Y, *et al. Vibrio parahaemolyticus* chromosomal *qnr* homologue VPA0095: demonstration by transformation with a mutated gene of its potential to reduce quinolone susceptibility in *Escherichia coli*. *Antimicrob Agents Chemother* 2005; 49: 2144-5.
182. Sakazaki R. "Bacteriology of Vibrio and related organisms". In *Cholera*. Plenum Medical Book Company, New York; 1992. p. 37-55.
183. Salyers AA and Whitt DD. Bacterial pathogenesis: a molecular approach. 2nd ed., ASM Press 2002; 168-84.

184. Sanchez MB, Hernandez A, Rodriguez-Martinez JM, *et al*. Predictive analysis of transmissible quinolone resistance indicates *Stenotrophomonas maltophilia* as a potential source of a novel family of Qnr determinants. *BMC Microbiol* 2008; 8: 148.
185. Sanders CC. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. *Clin Infect Dis* 2001; 32 Suppl 1: S1-8.
186. Saravanos K and Duff P. The quinolone antibiotics. *Obstet Gynecol Clin North Am* 1992; 19: 529-37.
187. Sarkar BL, Kanungo S and Nair GB. How endemic is cholera in India? *Indian J Med Res* 2012; 135: 246-8.
188. Sen B, Dutta B, Chatterjee S, *et al.* The first outbreak of acute diarrhea due to a pandemic strain of *Vibrio parahaemolyticus* O3:K6 in Kolkata, India. *Int J Infect Dis* 2007; 11: 185-7.
189. Shen LL, Kohlbrenner WE, Weigl D, *et al.* Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. *J Biol Chem* 1989; 264: 2973-8.
190. Singh A and Fleurat M. Pediatric emergency medicine practice acute gastroenteritis- an update. *Pediatr Emerg Med Pract* 2010;7: 1-20.
191. Singh AK, Haldar R, Mandal D, *et al.* Analysis of the topology of *Vibrio cholerae* NorM and identification of amino acid residues involved in norfloxacin resistance. *Antimicrob Agents Chemother* 2006; 50: 3717-23.
192. Singh R, Rajpara N, Tak J, *et al.* Clinical isolates of *Vibrio fluvialis* from Kolkata, India, obtained during 2006: plasmids, the *qnr* gene and a mutation in gyrase A as mechanisms of multidrug resistance. *J Med Microbiol* 2012; 61: 369-74.
193. Sjolund-Karlsson M, Reimer A, Folster JP, *et al.* Drug-resistance mechanisms in *Vibrio cholerae* O1 outbreak strain, Haiti, 2010. *Emerg Infect Dis* 2011; 17: 2151-4.
194. Srinivasan VB, Virk RK, Kaundal A, *et al.* Mechanism of drug resistance in clonally related clinical isolates of *Vibrio fluvialis* isolated in Kolkata, India. *Antimicrob Agents Chemother* 2006; 50: 2428-32.
195. Strahilevitz J, Jacoby GA, Hooper DC, *et al.* Plasmid-mediated quinolone resistance: a multifaceted threat. *Clin Microbiol Rev* 2009; 22: 664-89.
196. Sur D, Ramamurthy T, Deen J *et al.* Shigellosis : challenges & management issues. *Indian J Med Res* 2004; 120: 454-62
197. Talukder KA, Khajanchi BK, Islam MA, *et al.* Genetic relatedness of ciprofloxacin-resistant *Shigella dysenteriae* type 1 strains isolated in south Asia. *J Antimicrob Chemother* 2004; 54: 730-4.
198. Talukder KA, Khajanchi BK, Islam MA, *et al.* Fluoroquinolone resistance linked to both gyrA and parC mutations in the quinolone resistance-determining region of *Shigella dysenteriae* type 1. *Curr Microbiol* 2006; 52: 108-11.
199. Tamura K, Stecher G, Peterson D *et al*. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. *Mol Biol Evol* 2013; 30: 2725-9.
200. Tanabe K, Nakamura S and Kunii O. [Bacterological survey of diarrheal epidemics in the 1998 Bangladesh floods]. *Kansenshogaku zasshi* 1999; 73: 918-22.

201. Taneja N. Changing epidemiology of shigellosis and emergence of ciprofloxacin-resistant *Shigellae* in India. *J Clin Microbiol* 2007; 45: 678-9.
202. Taneja N, Mishra A, Kumar A *et al.* Enhanced resistance to fluoroquinolones in laboratory-grown mutants & clinical isolates of *Shigella* due to synergism between efflux pump expression & mutations in quinolone resistance determining region. *Indian J Med Res* 2015; 141: 81-9.
203. Tarr CL, Patel JS, Puhr ND *et al.* Identification of *Vibrio* isolates by a multiplex PCR assay and *rpoB* sequence determination. *J Clin Microbiol* 2007; 45:134-140.
204. Thekdi R, Lakhani AG, Vachha SM, *et al. Vibrio fluvialis* (group F vibrio) in Maharashtra. *Indian J Med Res* 1982; 76: 80-5.
205. Thompson FL, Iida T and Swings J. Biodiversity of *Vibrios*. *Microbiol Mol Biol Rev* 2004; 68: 403-31.
206. Thungapathra M, Amita, Sinha KK *et al.* Occurrence of antibiotic resistance gene cassettes *aac(6')-Ib*, *dfrA5*, *dfrA12*, and *ereA2* in class I integrons in non-O1, non-O139 *Vibrio cholerae* strains in India. *Antimicrob Agents Chemother* 2002; 46: 2948-55.
207. Tracz DM, Backhouse PG, Olson AB, *et al.* Rapid detection of *Vibrio* species using liquid microsphere arrays and real-time PCR targeting the *ftsZ* locus. *J Med Microbiol* 2007; 56: 56-65.
208. Tran JH and Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. *Proc Natl Acad Sci U S A* 2002; 99: 5638-42.
209. Tran JH, Jacoby GA and Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein Qnr with *Escherichia coli* DNA gyrase. *Antimicrob Agents Chemother* 2005a; 49: 118-25.
210. Tran JH, Jacoby GA and Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein QnrA with *Escherichia coli* topoisomerase IV. *Antimicrob Agents Chemother* 2005b; 49: 3050-2.
211. UNICEF and WHO, Diarrhoea: Why children are still dying and what can be done, UNICEF, New York, 2009.
212. Van Bambeke F, Michot JM, Van Eldere J, *et al.* Quinolones in 2005: an update. *Clin Microbiol Infect* 2005; 11: 256-80.
213. Vetting MW, Hegde SS, Fajardo JE, *et al.* Pentapeptide repeat proteins. *Biochemistry* 2006; 45: 1-10.
214. Vetting MW, Hegde SS, Wang M *et al.* Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor. *J Biol Chem* 2011; 286: 25265-73.
215. Vinothkumar K, Bhardwaj AK, Ramamurthy T *et al.* Triplex PCR assay for the rapid identification of 3 major *Vibrio* species, *Vibrio cholerae*, *Vibrio parahaemolyticus*, and *Vibrio fluvialis*. *Diagn Microbiol Infect Dis* 2013; 76: 526-8.
216. Vinothkumar K, Kumar GN and Bhardwaj AK. Characterization of *Vibrio fluvialis qnrVC5* gene in native and heterologous hosts: Synergy of *qnrVC5* with other determinants in conferring quinolone resistance. *Front Microbiol* 2016; 7:146.
217. Wang H, Dzink-Fox JL, Chen M, *et al.* Genetic characterization of highly fluoroquinolone-resistant clinical *Escherichia coli* strains from China: role of *acrR* mutations. *Antimicrob Agents Chemother* 2001; 45: 1515-21.

218. Walker RC. The fluoroquinolones. *Mayo Clin Proc* 1999; 74: 1030-7.
219. Watson JD, Baker TA, Bell SP et al. Molecular biology of the gene, 5th ed.; Cold Spring Harbour Laboratory Press 2004; pp. 115-22.
220. WGO. World gastroenterology organization practice guidelines. March 2008.
221. WHO. Antimicrobial resistance: Global report on surveillance. April 2014; ISBN: 9789241564748.
222. WHO. The global burden of disease: 2004 update. WHO press 2008; ISBN: 9789241563710.
223. Wohlkonig A, Chan PF, Fosberry AP, *et al.* Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. *Nat Struct Mol Biol* 2010; 17: 1152-3.
224. Xia R, Ren Y and Xu H. Identification of plasmid-mediated quinolone resistance *qnr* genes in multidrug-resistant Gram-negative bacteria from hospital wastewaters and receiving waters in the Jinan area, China. *Microb Drug Resist* 2013; 19: 446-56.
225. Xiong X, Bromley EH, Oelschlaeger P *et al.* Structural insights into quinolone antibiotic resistance mediated by pentapeptide repeat proteins: conserved surface loops direct the activity of a Qnr protein from a gram-negative bacterium. *Nucleic Acids Res* 2011; 39: 3917-27.
226. Xiong Z, Li J, Li T, *et al.* Prevalence of plasmid-mediated quinolone-resistance determinants in *Shigella flexneri* isolates from Anhui Province, China. *J Antibiot* 2010; 63: 187-9.
227. Yamane K, Wachino J, Suzuki S, *et al.* New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an *Escherichia coli* clinical isolate. *Antimicrob Agents Chemother* 2007; 51: 3354-60.
228. Yang H, Duan G, Zhu J, *et al.* Prevalence and characterisation of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes among *Shigella* isolates from Henan, China, between 2001 and 2008. *Int J Antimicrob Agents* 2013; 42: 173-7.
229. Yoshida H, Bogaki M, Nakamura M, *et al.* Quinolone resistance-determining region in the DNA gyrase *gyrA* gene of *Escherichia coli*. *Antimicrob Agents Chemother* 1990; 34: 1271-2.
230. Yu S, Chen W, Wang D *et al.* Species-specific PCR detection of the food-borne pathogen *Vibrio parahaemolyticus* using the *irgB* gene identified by comparative genomic analysis. *FEMS Microbiol Lett* 2010; 307: 65-71.
231. Zhang Y. I-TASSER server for protein 3D structure prediction. *BMC Bioinformatics* 2008; 9: 40.
232. Zhang W, Luo Y, Li J, *et al.* Wide dissemination of multidrug-resistant *Shigella* isolates in China. *J Antimicrob Chemother* 2011; 66: 2527-35.
233. Zhao J, Chen Z, Chen S *et al.* Prevalence and dissemination of *oqxAB* in *Escherichia coli* isolates from animals, farmworkers, and the environment. *Antimicrob Agents Chemother* 2010; 54: 4219-24.
234. Zhou Y, Yu L, Li J, *et al.* Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in *Vibrio cholerae* O139 strains. *Int J Antimicrob Agents* 2013; 42: 72-5.

235. Zhu JM, Jiang RJ, Kong HS, *et al.* Emergence of novel variants of *gyrA*, *parC*, *qnrS* genes in multi-drug resistant *Klebsiella* caused pneumonia. *Zhonghua Liu Xing Bing Xue Za Zhi* 2013a; 34: 61-6.
236. Zhu YL, Yang HF, Liu YY, *et al.* Detection of plasmid-mediated quinolone resistance determinants and the emergence of multidrug resistance in clinical isolates of *Shigella* in SiXian area, China. *Diagn Microbiol Infect Dis* 2013b; 75: 327-9.